Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Bioage Labs Inc (BIOA)

Bioage Labs Inc (BIOA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk GlobeNewswire - Tue Jun 16, 7:00AM CDT

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk...

BIOA : 20.77 (+3.90%)
MarketBeat.com
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease MarketBeat - Sat Jun 6, 7:04AM CDT

BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts...

BIOA : 20.77 (+3.90%)
BioAge Labs to Present at Upcoming Investor Conferences GlobeNewswire - Fri May 22, 8:00AM CDT

EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic...

BIOA : 20.77 (+3.90%)
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets FinancialNewsMedia - Wed May 20, 8:45AM CDT

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

AVAI : 0.1600 (-5.88%)
BIOA : 20.77 (+3.90%)
LCTX : 1.2100 (-3.20%)
GERN : 1.2600 (+2.44%)
FATE : 2.09 (+6.63%)
BioAge Labs Enters Its First Quarter Judged Entirely on Pipeline Execution Barchart - Mon May 11, 4:02PM CDT

Barchart Research What to Expect from BIOA Earnings BIOA Generated May 11, 2026 Current Price $18.16 EPS Estimate $$-0.69 Consensus Rating Moderate Buy Average Move 6.27% BioAge Labs Enters Its First Quarter...

BIOA : 20.77 (+3.90%)
MarketBeat.com
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials MarketBeat - Fri May 8, 2:12PM CDT

BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular...

BIOA : 20.77 (+3.90%)
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire - Fri May 8, 8:00AM CDT

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept...

BIOA : 20.77 (+3.90%)
Can BioAge Labs Break Its Pattern of Wider Losses Before Tomorrow's Report? Barchart - Mon May 4, 4:04PM CDT

Barchart Research What to Expect from BIOA Earnings BIOA Generated May 4, 2026 Current Price $16.62 EPS Estimate $$-0.71 Consensus Rating Moderate Buy Average Move 6.27% Can BioAge Labs Break Its Pattern...

BIOA : 20.77 (+3.90%)
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 GlobeNewswire - Mon May 4, 3:30PM CDT

Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease...

BIOA : 20.77 (+3.90%)
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP GlobeNewswire - Tue Apr 21, 6:00AM CDT

120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all...

BIOA : 20.77 (+3.90%)

Barchart Exclusives

Microsoft vs. Nvidia: Which AI Giant Is the Better Dividend Stock for the Long Haul? Barchart - 1 hour ago
Microsoft and NVIDIA are AI giants, but which stock is the better buy? Compare growth, valuation, dividends, and Wall Street ratings. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.